1. Introduction

Cross-Platform Genomic Data Standards refer to the technical, legal, ethical and regulatory rules that enable genomic information to be collected, stored, processed, exchanged, interpreted and transferred between different healthcare institutions, genomic laboratories, biotechnology companies, research organisations, hospitals, diagnostic platforms and government databases.

Genomic data includes:

DNA sequences and whole-genome sequencing information.

RNA sequencing and gene-expression information.

Genetic mutations and variants.

Chromosomal and hereditary information.

Pharmacogenomic data concerning drug responses.

Clinical genomic test results.

Family-linked genetic information.

Population-level genomic datasets.

The central legal problem is that different platforms may use different data formats, terminology, coding systems, security protocols and interpretation methods. This can lead to inaccurate diagnoses, incorrect variant classification, privacy violations, discriminatory decisions and wrongful medical treatment.

The central legal question is: Who is legally responsible when genomic information is incorrectly translated, transferred, interpreted or used because two genomic platforms follow incompatible standards?

Cross-platform genomic data standardisation therefore involves the intersection of biotechnology law, health-data protection, medical negligence, intellectual property, cybersecurity, research ethics, administrative law and international data governance.

2. Meaning and Scope of Cross-Platform Genomic Interoperability

Interoperability means that different technological systems can exchange information and correctly understand and use the information received.

For example, consider a patient whose genomic information is generated by Laboratory A, transferred to Hospital B, analysed through Software Platform C and subsequently used by a pharmaceutical company for precision-medicine research.

Illustrative genomic data exchange

Laboratory A

DNA sequencing and variant identification

Standardisation Layer

Common formats, identifiers, terminology and metadata

Hospital B

Clinical interpretation and treatment decisions

Platform C

Research, analytics and precision medicine

Each transfer must preserve accuracy, provenance, privacy and the original scientific meaning of the genomic information.

Interoperability has five important dimensions:

Technical interoperability: Systems can exchange genomic files.

Syntactic interoperability: Systems can recognise the structure and format of exchanged information.

Semantic interoperability: Systems understand the same genetic variant, terminology and clinical meaning.

Organisational interoperability: Institutions establish compatible policies, responsibilities and procedures.

Legal interoperability: Data transfers comply with applicable privacy, consent, confidentiality, research and international-transfer requirements.

A platform may be technically interoperable but legally non-compliant. For example, a hospital may successfully transmit genomic information to a foreign research institution without having a lawful basis for that disclosure.

3. Major International Genomic Data Standards

Several international standards and frameworks are relevant to cross-platform genomic interoperability.

A. HL7 FHIR Genomics

HL7 FHIR provides a framework for exchanging healthcare information.

Its genomics-related resources support the representation and exchange of genetic observations, diagnostic reports and related clinical information.

Legal importance:

Supports consistent communication of genomic findings.

Helps reduce transcription and interpretation errors.

Supports integration between laboratory and hospital systems.

Facilitates traceability of genomic test results.

FHIR implementation does not automatically establish legal consent or privacy compliance.

B. GA4GH Standards

Global Alliance for Genomics and Health (GA4GH) develops international standards and frameworks for responsible genomic and health-data sharing.

Important initiatives include:

Data Use Ontology (DUO).

Variation Representation Specification (VRS).

Beacon standards.

Phenopackets.

Genomic data-sharing frameworks.

Responsible data-access and governance principles.

These standards support consistent representation, discovery and controlled exchange of genomic information.

C. HGVS Nomenclature

Human Genome Variation Society (HGVS) nomenclature provides internationally recognised conventions for describing sequence variants.

Its legal significance is considerable because two laboratories may describe the same genetic alteration differently.

Standardised nomenclature assists:

Clinical interpretation.

Laboratory quality control.

Expert evidence in litigation.

Reproducibility of research.

Identification of discrepancies between reports.

D. VCF and SAM/BAM/CRAM Formats

VCF (Variant Call Format) is widely used to represent genetic variants.

SAM/BAM/CRAM formats are used for storing and exchanging sequencing alignment information.

These formats help facilitate technical exchange but do not independently guarantee the accuracy of genomic interpretation.

E. ISO Standards

Relevant standardisation work includes:

ISO 15189: Medical laboratories — requirements for quality and competence.

ISO/IEC 27001: Information security management systems.

ISO/IEC 27701: Privacy information management.

ISO 20387: Biotechnology — biobanking — general requirements.

ISO 23494 series: Biotechnology — provenance information model for biological material and data.

Compliance with an ISO standard does not automatically create a statutory defence against negligence or privacy liability.

4. International Legal Framework

A. WHO Genomic Data Governance Framework

The World Health Organization (WHO) published its Guidance for Human Genome Data Collection, Access, Use and Sharing on 20 November 2024.

The framework addresses:

Individual autonomy and informed consent.

Privacy and confidentiality.

Equitable access to genomic research.

Responsible international data sharing.

Scientific integrity and data quality.

Transparency and institutional accountability.

Fair distribution of benefits arising from genomic research.

The guidance is particularly important because genomic data can reveal information not only about an individual but also about biological relatives and communities.

It is an international governance framework, not a directly enforceable treaty. Its principles can nevertheless influence national legislation, institutional policies and judicial interpretation.

World Health Organization+1

B. GDPR and Cross-Border Genomic Information

The General Data Protection Regulation (GDPR) regulates personal data processing in the European Union.

Important provisions include:

Legal issue: A genomic platform cannot assume that because a patient has consented to genetic testing, every subsequent transfer to another laboratory, research database or commercial entity is automatically lawful.

The purpose, legal basis, recipient, safeguards and any applicable research exceptions must be examined separately.

C. GA4GH Responsible Data-Sharing Framework

The Global Alliance for Genomics and Health provides an important model for responsible genomic data sharing.

Its standards include:

Data Use Ontology (DUO).

Variation Representation Specification (VRS).

GA4GH Passports.

Beacon.

Data Access Committee Review Standards.

Data Privacy and Security Policy.

Consent Policy.

Ethical Provenance Toolkit.

DUO is particularly significant because it allows data-use restrictions to be represented in a machine-readable manner.

For example, a dataset may be authorised for cancer research but not for commercial ancestry profiling.

A receiving platform should therefore check the authorised purpose before permitting access.

GA4GH standards are voluntary technical and governance instruments unless incorporated into contracts, institutional policies or applicable law.

ga4gh.org+3

5. India: Legal Framework for Cross-Platform Genomic Data Standards

India presents important regulatory questions because genomic data may pass between private diagnostic laboratories, public hospitals, biotechnology companies, research institutions and international collaborators.

A. Digital Personal Data Protection Act, 2023

The Digital Personal Data Protection Act, 2023 is an important part of India's legal framework.

Where genomic information is digital personal data relating to an identifiable individual, its processing may fall within the Act.

Important compliance issues include:

Lawful processing.

Notice and consent where applicable.

Purpose limitation.

Accuracy and completeness where personal data is used to make decisions or disclosed to another data fiduciary.

Reasonable security safeguards.

Breach-related obligations.

Rights of data principals.

Obligations of data fiduciaries and processors.

A particularly important distinction is that the DPDP Act does not create a separate statutory category specifically called sensitive genomic data. Genomic information must nevertheless be protected under the applicable personal-data obligations, and its highly consequential nature should inform security and governance measures.

The Act also provides for certain exemptions, including specified research-related processing subject to statutory conditions. An institution cannot assume that every genomic research activity is exempt.

B. Constitutional Right to Privacy

Article 21 of the Constitution of India protects life and personal liberty. Articles 14 and 19 may also become relevant where genomic information is used in discriminatory or arbitrary governmental decision-making.

Genomic privacy can involve:

Bodily autonomy.

Informational self-determination.

Genetic identity.

Family privacy.

Reproductive autonomy.

Protection against genetic discrimination.

The constitutional question becomes particularly important when government authorities establish large-scale genomic databases or share genetic information between public institutions.

C. Indian Council of Medical Research Guidelines

The Indian Council of Medical Research (ICMR) provides ethical guidance for biomedical and health research involving human participants.

Its National Ethical Guidelines for Biomedical and Health Research Involving Human Participants (2017) are relevant to genomic research involving:

Informed consent.

Biological samples.

Genetic information.

Confidentiality.

Secondary use of research data.

Vulnerable participants.

Ethics Committee oversight.

International research collaborations.

These guidelines help establish ethical standards for research institutions and Ethics Committees. Their legal enforceability depends on the applicable regulatory, institutional and contractual framework.

D. Information Technology and Cybersecurity Requirements

The Information Technology Act, 2000 and applicable rules remain relevant to cybersecurity and certain forms of electronic-data protection, subject to the operation of the DPDP framework and transitional provisions.

Relevant issues include:

Unauthorised access to genomic databases.

Disclosure of genetic information.

Data breaches.

Weak authentication systems.

Improper transfer of genomic files.

Failure to maintain appropriate security controls.

E. ABDM and Health Information Standards

The Ayushman Bharat Digital Mission (ABDM) promotes interoperable digital health infrastructure in India.

Its health-data exchange architecture is relevant to the exchange of clinical information between healthcare providers.

However, ordinary health-record interoperability does not automatically resolve all the scientific requirements of genomic data interoperability. Genomic sequencing reports require additional standardisation of variants, reference sequences, laboratory metadata, clinical interpretations and provenance.

6. Important Case Laws and Their Legal Significance

An important qualification is necessary: there is no established universal judicial doctrine specifically requiring every genomic platform to adopt one common technical standard. The following cases provide relevant principles concerning privacy, consent, genetic information, scientific information, data ownership and liability.

Case 1. Justice K.S. Puttaswamy (Retd.) v. Union of India (2017)

Supreme Court of India

Citation: (2017) 10 SCC 1; 2017 INSC 801.

Facts and background:

A nine-judge Constitution Bench considered whether the right to privacy was protected as a fundamental right under the Indian Constitution.

Judgment:

The Supreme Court unanimously recognised privacy as a constitutionally protected fundamental right, principally under Article 21 and other freedoms guaranteed by Part III.

Relevance to genomic interoperability:

This judgment provides an important constitutional foundation for protecting genomic information.

Suppose a hospital transfers a patient's whole-genome sequence to an external research platform without an appropriate legal basis.

The transfer may raise constitutional privacy concerns, particularly where a public authority is involved.

The judgment supports the following principles:

Informational privacy.

Individual autonomy.

Purpose limitation.

Proportionality.

Protection against unjustified data collection.

Accountability in the use of personal information.

Legal principle: Technological efficiency cannot automatically justify unrestricted collection, exchange or retention of highly personal information.

Sci API+1

Case 2. Samira Kohli v. Dr. Prabha Manchanda (2008)

Supreme Court of India

Citation: (2008) 2 SCC 1.

Facts:

The case concerned medical procedures performed without obtaining the patient's valid consent for the additional procedure.

Judgment:

The Supreme Court explained that valid consent requires competence, voluntariness and adequate information about the nature and purpose of the procedure.

Consent to one medical procedure does not automatically authorise an entirely different procedure.

Relevance to genomic data standards:

A patient may consent to diagnostic genetic testing but not necessarily to:

Uploading the genomic information to an international database.

Commercial research.

Pharmaceutical development.

Population-genomics research.

Genetic ancestry analysis.

Sharing information with unrelated commercial entities.

Consent must be assessed according to the proposed activity and applicable legal requirements.

Legal principle: Consent for genomic testing should not be treated as unrestricted permission for every subsequent use of genomic information.

Indian Kanoon+1

Case 3. S. and Marper v. United Kingdom (2008)

European Court of Human Rights

Citation: Applications Nos. 30562/04 and 30566/04; Grand Chamber judgment, 4 December 2008.

Facts:

The applicants challenged the retention of their fingerprints, cellular samples and DNA profiles after criminal proceedings had ended without conviction.

Judgment:

The European Court of Human Rights found a violation of Article 8 of the European Convention on Human Rights.

It emphasised the sensitive character of DNA information and the privacy implications of retaining genetic material and profiles.

Relevance to genomic interoperability:

The case establishes that DNA information is not merely ordinary administrative information.

Cross-platform sharing must consider:

Whether retention remains necessary.

Whether the purpose of processing is legitimate.

Whether access is proportionate.

Whether appropriate safeguards exist.

Whether retention periods are justified.

Whether the individual can challenge unlawful processing.

Legal principle: Genetic information requires heightened privacy protection, and indiscriminate retention or processing can violate fundamental privacy rights.

HUDOC+1

Case 4. Association for Molecular Pathology v. Myriad Genetics, Inc. (2013)

US Supreme Court

Citation: 569 U.S. 576 (2013).

Facts:

Myriad Genetics obtained patents relating to BRCA1 and BRCA2 genes, which are associated with increased risks of breast and ovarian cancer.

The dispute concerned whether isolated naturally occurring DNA sequences could be patented.

Judgment:

The US Supreme Court held that naturally occurring DNA segments are not patent-eligible merely because they have been isolated.

However, synthetically created complementary DNA (cDNA) may be patent-eligible because it is not naturally occurring in the same form.

Relevance to genomic interoperability:

The judgment is important when genomic information is exchanged between laboratories and commercial biotechnology platforms.

It raises questions about:

Ownership of genetic information.

Patent rights in genomic technologies.

Commercial control of diagnostic methods.

Research access.

Licensing restrictions.

Competition in genetic testing.

Legal principle: Discovering or isolating naturally occurring genetic information does not, by itself, create patent rights over that information.

This case is not a direct ruling on genomic data exchange, but it is significant for the intellectual-property dimension of genomic standardisation.

Justia U.S. Supreme Court Center

Case 5. Moore v. Regents of the University of California (1990)

Citation: 51 Cal. 3d 120; 793 P.2d 479 (Cal. 1990).

Facts:

John Moore's biological materials were used in research that resulted in the development of a commercially valuable cell line without adequate disclosure of the relevant financial interests.

Judgment:

The California Supreme Court rejected Moore's conversion claim based on the excised cells but recognised the importance of informed consent and disclosure of conflicts of interest.

Relevance:

Genomic platforms frequently process biological samples and sequence-derived information.

This case raises important questions about:

Commercial use of biological materials.

Research disclosure.

Patient consent.

Institutional conflicts of interest.

Ownership claims over biological derivatives.

It does not establish that a laboratory owns all genomic data generated from a patient's sample.

Case 6. Greenberg v. Miami Children's Hospital Research Institute (2003)

Citation: 264 F. Supp. 2d 1064 (S.D. Fla. 2003).

Facts:

The dispute involved genetic research relating to Canavan disease and the use of genetic information and research contributions by affected families.

Legal significance:

The case considered claims relating to informed consent, unjust enrichment, fiduciary duties and the commercialisation of genetic research.

Relevance to interoperability:

When genomic information is shared between institutions, research agreements should address:

Permitted research purposes.

Commercial exploitation.

Attribution and acknowledgement.

Benefit-sharing.

Restrictions on downstream use.

Responsibilities towards research participants.

The case illustrates why technical data exchange must be accompanied by enforceable governance arrangements.

7. Legal Problems Arising from Incompatible Genomic Platforms

A. Genomic Data Translation Errors

Different platforms may interpret the same genetic variant differently.

For example, Laboratory A may identify a variant as clinically significant, whereas Platform B may incorrectly classify it as benign because of incompatible reference sequences or outdated annotation databases.

Possible legal consequences:

Medical negligence.

Defective diagnostic services.

Professional misconduct.

Consumer protection claims.

Institutional liability.

The laboratory must maintain appropriate quality-control procedures and communicate relevant limitations.

B. Incorrect Variant Identification

Incorrect genetic variant representation may lead to:

False-positive diagnoses.

False-negative diagnoses.

Unnecessary treatment.

Delayed treatment.

Incorrect reproductive counselling.

Inappropriate drug selection.

A court examining such a dispute may consider professional standards, laboratory accreditation, scientific reliability, causation and foreseeable harm.

C. Unauthorised Cross-Platform Disclosure

A genomic database may transfer patient information to another platform without appropriate authorisation.

Potential violations include:

Privacy legislation.

Confidentiality obligations.

Research consent conditions.

Contractual restrictions.

Cybersecurity requirements.

D. Algorithmic Interpretation Differences

Artificial intelligence systems may interpret genomic variants differently because of differences in training datasets, reference populations and computational methods.

This creates potential liability where an institution relies on an inadequately validated algorithm for clinical decision-making.

E. Genetic Discrimination

Genomic data may reveal predispositions to hereditary diseases.

Unauthorised access or misuse may lead to discrimination in:

Employment.

Insurance.

Financial services.

Reproductive services.

Healthcare access.

Genomic interoperability standards should therefore incorporate restrictions on discriminatory secondary use.

F. Loss of Genomic Provenance

Provenance means the documented history of genomic information, including its source, processing, transformation and interpretation.

If a genomic report cannot be traced back to its original sequencing laboratory, reference genome and analytical pipeline, its reliability may be challenged.

This can create difficulties in medical negligence litigation, research disputes and criminal proceedings.

8. Liability and Accountability Framework

Different participants may have different legal responsibilities.

Liability is not automatic merely because a technical error occurs. The claimant must establish the relevant legal duty, breach, causation and legally recognised harm, subject to the applicable statutory regime.

9. Contractual Regulation of Cross-Platform Genomic Data

Institutions exchanging genomic data should establish detailed data-sharing agreements.

Important contractual provisions include:

Technical compatibility: Identification of accepted genomic file formats and data schemas.

Reference genome identification: Specification of the reference assembly and version.

Data accuracy: Responsibilities for checking and correcting errors.

Data provenance: Documentation of sequencing and analytical procedures.

Consent restrictions: Permitted purposes and prohibited secondary uses.

Cybersecurity: Encryption, authentication and access controls.

Data retention: Retention periods and deletion obligations.

Incident reporting: Notification and investigation of security incidents.

Liability allocation: Responsibility for errors, misuse and unauthorised disclosures.

Dispute resolution: Applicable law, jurisdiction and dispute-resolution procedures.

A particularly important contractual requirement is that the receiving institution must not silently alter the scientific meaning of genomic information during data conversion.

10. Australia: Genomic Data Standards and Regulatory Accountability

Australia provides another important legal framework for genomic interoperability.

Relevant legislation and institutions include:

Genetic information is recognised as sensitive information under Australia's privacy framework.

The Australian Law Reform Commission's report Essentially Yours: The Protection of Human Genetic Information in Australia (ALRC Report 96) examined the difficulties of applying privacy legislation to genetic samples and derived genetic information.

It highlighted the distinction between a physical biological sample and information derived from that sample.

ALRC+1

Australian accountability issues

1. Laboratory interoperability

Laboratories must maintain reliable processes for producing and transferring genomic results.

2. Genetic privacy

Genomic information must be protected against unauthorised access and disclosure.

3. Research governance

Research institutions must respect consent conditions, ethics approval and applicable data-sharing restrictions.

4. International transfers

Overseas genomic data sharing must be assessed against applicable privacy and contractual requirements.

5. Regulatory oversight

The relevant regulator must ensure that regulated activities comply with the applicable statutory framework.

11. Evidence and Litigation in Genomic Interoperability Disputes

Where incompatible genomic platforms cause harm, courts may require scientific and technical evidence.

Important evidentiary materials include:

Original sequencing files.

VCF files and sequence-alignment records.

Laboratory quality-control reports.

Reference genome versions.

Variant classification records.

Software version histories.

Audit trails.

Data-sharing agreements.

Consent documents.

Expert witness reports.

Cybersecurity incident records.

Scientific reliability and expert evidence

Courts must distinguish between:

Accuracy of the original genomic sequence.

Accuracy of the computational transformation.

Reliability of variant interpretation.

Clinical significance of the identified variant.

Causal connection between the error and the patient's injury.

An expert should explain whether the discrepancy resulted from a technical conversion error, scientific disagreement, inadequate validation or negligent clinical interpretation.

A genomic report should not be treated as automatically reliable simply because it was generated by an accredited laboratory or internationally recognised platform.

12. Proposed Regulatory Model for Cross-Platform Genomic Standards

A comprehensive regulatory model should combine international technical standards with legally enforceable accountability.

Proposed seven-layer regulatory architecture

Standardised data formats

Common genomic file structures and exchange protocols.

Semantic harmonisation

Consistent variant terminology, identifiers and reference sequences.

Data quality assurance

Validation, laboratory accreditation and reproducibility.

Consent and purpose control

Legally compliant permissions and restrictions on secondary use.

Privacy and cybersecurity

Encryption, authentication, access restrictions and breach management.

Provenance and accountability

Traceable records of every transfer, modification and interpretation.

Independent regulatory supervision

Audits, complaints, corrective directions and appropriate penalties.

Suggested regulatory reforms

Governments should consider:

Establishing minimum genomic interoperability requirements.

Requiring standardised sequencing metadata.

Creating common variant-identification protocols.

Requiring documented reference genome versions.

Introducing machine-readable consent restrictions.

Establishing cross-border genomic data-sharing agreements.

Creating independent audit mechanisms.

Establishing procedures for correcting erroneous genomic records.

Developing rules for AI-assisted genomic interpretation.

Providing effective remedies for affected individuals.

13. Important International Standards: Comparative Table

Of particular importance is ISO/TS 20428:2024, which defines data elements and metadata for structured clinical genomic sequencing information in electronic health records. It specifically addresses DNA-level variation generated through next-generation sequencing.

ISO+2

14. Emerging Legal Challenges

The future of genomic interoperability will create additional legal questions.

A. AI-generated genomic interpretations

Who is liable when an AI system converts genomic information incorrectly and a doctor relies on the result?

B. Cross-border genomic sovereignty

Can a foreign institution use genomic information collected from an Indian population for commercial research without satisfying applicable legal and ethical requirements?

C. Genomic information and family privacy

Can one person's consent authorise disclosure of genetic information that also reveals information about relatives?

D. Long-term genomic data retention

How should institutions balance the future medical value of genomic records against privacy and deletion rights?

E. Genomic data portability

To what extent should patients be able to obtain their genomic information in a technically usable format and transfer it to another laboratory?

F. Algorithmic bias

Can a genomic platform be legally challenged when its reference datasets inadequately represent particular populations and produce systematically less reliable interpretations?

G. Commercial interoperability restrictions

Can proprietary genomic formats or restrictive software licences prevent hospitals and laboratories from transferring patient data to competing platforms?

These issues require a combination of technical standards, privacy regulation, competition law, medical accountability and constitutional safeguards.

15. Critical Legal Analysis

Cross-platform genomic data standards should not be understood as merely technical specifications.

They have a direct relationship with the rule of law because genomic information can influence medical treatment, reproductive decisions, insurance, research participation and individual privacy.

Three fundamental legal tensions emerge.

First: Interoperability versus privacy.

Greater genomic data exchange can improve medical research and diagnosis, but excessive sharing can undermine individual autonomy and confidentiality.

Second: Standardisation versus scientific innovation.

Common technical standards improve compatibility, but overly rigid requirements may prevent the adoption of new sequencing technologies and analytical methods.

Third: Data accessibility versus commercial ownership.

Patients and researchers need meaningful access to genomic information, but commercial platforms may seek to protect proprietary software, databases and analytical methods.

The appropriate legal approach is therefore not unrestricted data sharing or complete data isolation. It is controlled interoperability based on scientific accuracy, lawful processing, transparency, security and accountability.

16. Conclusion

Cross-Platform Genomic Data Standards are essential to the development of precision medicine, international genomic research, biotechnology innovation and digital healthcare.

The legal framework must ensure that genomic information retains its scientific meaning when transferred between different systems and institutions.

The principles established in Puttaswamy, Samira Kohli, S. and Marper, Myriad Genetics, Moore and Greenberg provide important foundations concerning privacy, consent, genetic information, commercialisation and research accountability.

However, these cases do not collectively establish a specific mandatory genomic interoperability code. That requires legislative and regulatory development.

The ultimate legal principle is that genomic interoperability must preserve three things simultaneously: scientific integrity, individual rights and institutional accountability.

17. Key Legal Authorities and Research References

For further academic research, the following primary materials are particularly useful:

Justice K.S. Puttaswamy v. Union of India (2017).

Samira Kohli v. Dr. Prabha Manchanda (2008).

S. and Marper v. United Kingdom (2008).

Association for Molecular Pathology v. Myriad Genetics (2013).

WHO Guidance on Human Genome Data (2024).

GA4GH Genomic Data Standards.

ISO/TS 20428:2024.

Australian Law Reform Commission – Genetic Information and Privacy.

Academic research direction: A particularly valuable advanced research topic is the development of a legally enforceable international genomic interoperability framework that combines GA4GH standards, ISO genomic specifications, national privacy legislation, informed consent and cross-border institutional liability.